WH
NTLA icon

William Harnisch’s Intellia Therapeutics NTLA Stock Holding History

William Harnisch’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$2.01M – 46
2021
Q3 		$2.01M Buy
+15,000
New +$2.27M 0.18% 16

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

William Harnisch's NTLA Position: Q4 2021 in Review

William Harnisch sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 15,000 shares — an estimated $2.01M sold.

William Harnisch first reported a position in NTLA in Q3 2021 and held it in 1 quarter. The position peaked at $2.01M in Q3 2021. 372 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • William Harnisch reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • William Harnisch sold 15,000 Intellia Therapeutics shares in Q4 2021, an estimated $2.01M.
  • William Harnisch first reported a position in Intellia Therapeutics in Q3 2021 and held it in 1 quarter.
  • William Harnisch's Intellia Therapeutics position peaked at $2.01M in Q3 2021.
  • 372 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Peconic Partners's 13F filing for Q4 2021, filed 14 Feb 2022.